Proteomics

Dataset Information

0

Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4/6 inhibition


ABSTRACT: Major histocompatibility complex (MHC) class I peptides play a critical role in immune cell recognition and can trigger an antitumor immune response in cancer. Surface MHC levels can be modulated by anticancer agents, altering immunity. However, understanding the peptide repertoire response to treatment remains challenging and is limited by quantitative mass spectrometry-based strategies lacking robust normalization controls. We describe a novel approach that leverages recombinant heavy isotope-coded peptide MHCs (hipMHCs) and multiplex isotope tagging to quantify peptide repertoire alterations using low sample input. HipMHCs improve quantitative accuracy of peptide repertoire changes by normalizing for variation across analyses and enable absolute quantification using internal calibrants to determine copies per cell of MHC antigens, which can inform targeted and combination immunotherapy design. Applying this platform to profile the immunopeptidome response to CDK4/6 inhibition and Interferon gamma, known modulators of antigen presentation, uncovered treatment-specific alterations, connecting the intracellular response to extracellular immune presentation.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Melanocyte, Epithelial Cell, Cell Culture

DISEASE(S): Brain Cancer,Breast Cancer

SUBMITTER: Lauren Stopfer  

LAB HEAD: Forest White

PROVIDER: PXD017407 | Pride | 2020-06-04

REPOSITORIES: Pride

altmetric image

Publications

Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4/6 inhibition.

Stopfer Lauren E LE   Mesfin Joshua M JM   Joughin Brian A BA   Lauffenburger Douglas A DA   White Forest M FM  

Nature communications 20200602 1


Peptides bound to class I major histocompatibility complexes (MHC) play a critical role in immune cell recognition and can trigger an antitumor immune response in cancer. Surface MHC levels can be modulated by anticancer agents, altering immunity. However, understanding the peptide repertoire's response to treatment remains challenging and is limited by quantitative mass spectrometry-based strategies lacking normalization controls. We describe an experimental platform that leverages recombinant  ...[more]

Similar Datasets

2020-04-29 | GSE144373 | GEO
2019-03-05 | PXD011444 | Pride
2021-12-06 | PXD024369 | Pride
2020-01-29 | PXD014644 | Pride
2017-03-27 | PXD004746 | Pride
2019-03-05 | PXD011464 | Pride
2021-09-09 | PXD020750 | Pride
2023-11-21 | PXD039584 | Pride
2021-06-07 | PXD024562 | Pride
2017-03-27 | PXD005704 | Pride